Workflow
事关AI医疗,科大讯飞最新发声!

Core Viewpoint - The company is focusing on the globalization of its medical AI, with plans to achieve profitability within the next 1-2 years, as stated by the president of iFlytek Medical, Tao Xiaodong [1][5]. Group 1: Globalization of Medical AI - iFlytek Medical has officially launched the international version of its Spark Medical Model V2.5 and the iFlytek Xiaoyi App in Hong Kong, which is seen as a bridgehead for internationalization [3]. - The upgraded Spark Medical Model V2.5 supports local language scenarios in Hong Kong and aims to provide localized capabilities for international cities [3]. - The company plans to collaborate with doctors familiar with Western medical systems in Hong Kong to develop technologies that have already been successfully applied in mainland China into global products [3][4]. Group 2: Financial Performance and Commercialization - iFlytek Medical reported a revenue of 734 million yuan for 2024, a year-on-year increase of 32%, but also a net loss of 133 million yuan, which is an 8.5% reduction compared to 2023 [6]. - The company has seen significant growth in both B-end and C-end business revenues, with C-end patient business revenue reaching 211 million yuan, up 56.6%, and B-end hospital business revenue at 132 million yuan, up 103.4% [7]. - The company’s AI assistant has been deployed in 69,200 grassroots medical institutions across 692 districts, providing over 1 billion AI-assisted diagnoses and correcting diagnoses 1.75 million times [6][7].